CCT 289346

Drug Profile

CCT 289346

Alternative Names: CCT289346

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Cancer Research
  • Developer Institute of Cancer Research; Phenex Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 17 May 2017 Institute of Cancer Research plans a phase I trial for Breast cancer (Combination therapy) (Institute of Cancer Research website, May 2017)
  • 01 Apr 2017 Preclinical trials in Breast cancer (Combination therapy) in United Kingdom (PO)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top